Shares of Uniqure NV (NASDAQ:QURE) have earned a consensus rating of “Hold” from the nine analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $19.40.
A number of research firms have weighed in on QURE. HC Wainwright began coverage on Uniqure in a report on Friday, December 1st. They issued a “buy” rating and a $28.00 target price on the stock. Oppenheimer reissued a “hold” rating on shares of Uniqure in a report on Friday, November 24th. ValuEngine downgraded Uniqure from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Evercore ISI began coverage on Uniqure in a report on Tuesday, November 7th. They issued an “outperform” rating and a $22.00 target price on the stock. Finally, Zacks Investment Research downgraded Uniqure from a “buy” rating to a “hold” rating in a report on Friday, November 10th.
Several hedge funds and other institutional investors have recently bought and sold shares of QURE. Mangrove Partners bought a new position in shares of Uniqure in the second quarter worth about $247,000. JPMorgan Chase & Co. grew its position in shares of Uniqure by 33.5% during the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 14,659 shares in the last quarter. OxFORD Asset Management LLP purchased a new stake in shares of Uniqure during the third quarter worth about $399,000. Finally, FMR LLC grew its position in shares of Uniqure by 4.1% during the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock worth $9,656,000 after purchasing an additional 61,650 shares in the last quarter. 24.87% of the stock is currently owned by hedge funds and other institutional investors.
Uniqure (NASDAQ QURE) traded up $0.85 during mid-day trading on Friday, reaching $17.86. The company’s stock had a trading volume of 273,300 shares, compared to its average volume of 317,609. Uniqure has a 52 week low of $4.72 and a 52 week high of $21.35. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.64 and a current ratio of 3.64.
Uniqure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.